Haematology Oncology Strong — universal standard for lymphoma staging; endorsed by NCCN and ESMO
Ann Arbor Staging for Lymphoma
Staging system for Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) based on the number and location of involved lymph node regions and extranodal sites. Guides treatment planning.
References
- Carbone PP, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31(11):1860–1861.
- Lister TA, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630–1636.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- International Prognostic Index (IPI) for DLBCL · Lymphoma
- CNS International Prognostic Index (CNS-IPI) for DLBCL · Lymphoma
- NCCN-IPI for Diffuse Large B-Cell Lymphoma · Lymphoma
- MALT Lymphoma International Prognostic Index (MALT-IPI) · Lymphoma
- Mantle Cell Lymphoma International Prognostic Index (MIPI) · Lymphoma
- R-IPI — Revised International Prognostic Index for DLBCL · Lymphoma
Drugs
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.